Market Place
Sourcing Support
Padagis Generic Loteprednol Etabonate Receives Approval in U.S
10 Jul 2024 //
FDA
Lupin`s Generic Loteprednol Etabonate Receives Approval in the U.S.
24 Apr 2024 //
FDA
Sun Pharma`s Generic Loteprednol Etabonate Receives Approval in the U.S.
09 Aug 2023 //
FDA
Enforcement Report - Week of July 26, 2023
26 Jul 2023 //
FDA
Kala buys time by selling eye disease drugs to Alcon for $60M
24 May 2022 //
FIERCEPHARMA
Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio
24 May 2022 //
BIOSPACE
Akorn Inc`s Generic Loteprednol Etabonate Receives Approval In US
16 Feb 2021 //
FDA
Akorn Inc`s Generic Loteprednol Etabonate Receives Approval In US
13 Feb 2021 //
FDA
Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%
11 Feb 2021 //
PRNEWSWIRE
Kala Announces FDA Acceptance of New Drug Application for EYSUVIS™
26 May 2020 //
BUSINESSWIRE
Kala Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
26 May 2020 //
BUSINESSWIRE
FARMABIOS S.P.A Fails EDQM Inspection
23 Nov 2019 //
EDQM
Hi-Tech `s Generic Loteprednol Etabonate Receives Approval in US
19 Apr 2019 //
FDA
Kala Pharmaceuticals Announces Pricing of Public Offering of 7,500,000 Shares
03 Oct 2018 //
BUSINESSWIRE
FDA approves Kala Pharma`s eye pain drug
24 Aug 2018 //
REUTERS
Massachusetts` Mucus Penetrating Eye Disease Firm Kala Pharma Raises $68 Million
13 Apr 2016 //
BIOSPACE
Valeant Announces New U.S. Fulfillment Agreements With Walgreens
16 Dec 2015 //
PR NEWS WIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.